Cocrystal Pharma Shares Upcoming Clinical Milestones at Investment Conferences
BOTHELL, Wash. — Cocrystal Pharma, Inc. (Nasdaq: COCP) is excited to announce its participation in the upcoming Virtual Investor Summit Microcap Forum as well as the H.C. Wainwright 26th Annual Global Investment Conference.
“We are eager to highlight significant near-term clinical milestones during these important investment conferences,” stated James Martin, CFO and co-CEO of Cocrystal. “We anticipate sharing topline results soon from our influenza A Phase 2a challenge study involving our innovative oral PB2 inhibitor, CC-42344, with a comprehensive report expected to be finalized next year. Additionally, we are thrilled to inform that topline results from the Phase 1 multiple-ascending cohorts for our novel oral protease inhibitor, CDI-988, which targets norovirus and coronavirus infections, are projected to be available by the end of this year or early next year.”
Conferences on the Horizon
Virtual Investor Summit Microcap Forum
The presentation and Q&A session will commence shortly, providing insights into Cocrystal's latest advancements.
H.C. Wainwright 26th Annual Global Investment Conference
An on-demand presentation will be accessible on the conference platform, enabling participants to interact with the management team in both in-person and virtual formats. This event is a vital opportunity for institutional investors and industry professionals to connect with the company.
Overview of Pipeline Products
CC-42344 – PB2 Inhibitor for Pandemic and Seasonal Influenza A
CC-42344 is Cocrystal's innovative antiviral candidate, specifically developed to tackle both pandemic and seasonal influenza A. This drug works by inhibiting the replication of the influenza A virus through binding to a conserved PB2 site. Currently, it is undergoing a Phase 2a challenge study in healthy volunteers, showing promising safety and pharmacokinetic profiles in previous trials.
CDI-988 – Protease Inhibitor for Noroviruses and Coronaviruses
CDI-988 is a cutting-edge protease inhibitor targeting noroviruses and coronaviruses, including variants of SARS-CoV-2. The design of CDI-988 aims to deliver broad-spectrum antiviral activity through a unique structural approach and is currently in a randomized Phase 1 trial assessing its safety and pharmacodynamics.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics aimed at inhibiting the replication of various viruses, including influenza, noroviruses, coronaviruses, and hepatitis C. By leveraging advanced structure-based technologies and specialized expertise, Cocrystal strives to produce first- and best-in-class antiviral medications.
Investor and Media Contact Information
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com
Frequently Asked Questions
1. What events will Cocrystal Pharma be presenting at?
Cocrystal Pharma will be presenting at the Virtual Investor Summit Microcap Forum and the H.C. Wainwright 26th Annual Global Investment Conference.
2. What key milestones does Cocrystal Pharma plan to showcase?
The company intends to highlight topline results from its influenza A Phase 2a challenge study and Phase 1 trials for its antiviral candidates, CC-42344 and CDI-988.
3. What is CC-42344 designed to treat?
CC-42344 is an antiviral candidate aimed at treating pandemic and seasonal influenza A by inhibiting the replication of the virus.
4. What conditions does CDI-988 target?
CDI-988 is focused on treating infections caused by noroviruses and coronaviruses, including variants of SARS-CoV-2.
5. How can investors contact Cocrystal Pharma?
Investors can contact Cocrystal Pharma through LHA Investor Relations by reaching out to Jody Cain at 310-691-7100 or via email at jcain@lhai.com.
